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ENHANCED CYTOTOXICITY OF РHOTOEXCITED 
FULLERENE C60  AND CISPLATIN COMBINATION AGAINST  DRUG-
RESISTANT LEUKEMIC CELLS
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Aim: To evaluate the viability of leukemic cells sensitive (L1210S) and resistant (L1210R) to cisplatin, ROS production and free 
cytosolic Ca2+ concentration under treatment with cisplatin or its combination with photoexcited fullerene C60. Methods: Cell vi-
ability was assessed by the MTT reduction assay. Light-emitting diode lamp (2.45 J/сm2) was used for photoexcitation of intracel-
lular accumulated fullerene C60. Free cytosolic calcium concentration ([Ca2+]i) and ROS production in cells were estimated with 
the use of fluorescent probes Indo-1 and 2′,7′-dichlorodihydrofluorescein diacetate (DCF-DA), respectively. Results: It is shown 
that viability of L1210R cells wasn’t changed under treatment with cisplatin in concentration range 0.1–10 μg/ml. 50% and 30% 
decrease of L1210S cells were observed after 24 h of incubation with cisplatin at concentrations 5 and 1 μg/ml, respectively. In-
tensification of extranuclear cytotoxic effects (ROS production and [Ca2+]i increase) after treatment with 1 μg/ml was detected 
in L1210S, but not in L1210R cells. The most strongly pronounced increase of ROS production and [Ca2+]i in both L1210 cell 
lines was revealed in dynamics after combined treatment with cisplatin (1 μg/ml) and photoexcited fullerene C60 (10–5 M) and was 
followed by decreased viability of not only L1210S, but of L1210R cells as well.. Conclusion: Combined treatment with photoex-
cited C60 and cisplatin allowed to decrease effective concentration of cisplatin against parental L1210 cells and to increase sensibil-
ity of resistant cells to the drug.
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Despite the fact that the most commonly used 
cytotoxic agents — cisplatin (CP), doxorubicin and pa-
clitaxel, are highly efficient in current cancer therapy; 
their therapeutic efficiency is lowered by high toxicity 
and easy development of drug resistance. CP displays 
clinical activity against variety of human malignancies 
and is generally recognized as the DNA-damaging 
drug. Nevertheless CP is shown to induce apoptosis in-
dependently of DNA damage; and the ability to activate 
several different rather than a single apoptotic pathway 
is thought to be a distinction, which makes CP highly 
efficient as an anticancer drug. Cytoplasmic reactive 
oxygen species (ROS) production, free cytosolic Ca2+ 
concentration increase, modification of membrane 
ion channels and transport proteins, endoplasmic 
reticulum stress are supposed to be the pathways 
of CP-induced cell death signaling [1].
Because CP has multiple cellular targets and many 
different routes of cell entry, resistance to this drug 
is very complex and requires numerous mechanisms 
including reduced accumulation by impaired influx 
or active efflux, defective endocytosis, detoxification 
by GSH system, inactivation of apoptotic pathways, 
increased DNA repair, alterations in the expression 
of tumor suppressor gene p53 [2–6]. To increase 
the therapeutic index and to minimize CP resistance 
combined therapies with the use of nanotechnologies 
are developing now.
The recent studies have showed that combination 
or conjunction of anticancer drugs with the representa-
tives of carbon nanostructures (single-walled carbon 
nanotubes, hydroxylated fullerene C60, metallofulle-
renes with gadolinium [Gd@C82(OH)22]n, etc.) could 
be promising for targeted drug delivery, overcoming 
of tumor cells drug resistance and reduction of toxic 
effects in normal cells [7–11].
To estimate the probability of enhancing CP pro-
apoptotic effects we have studied the effect of com-
bined treatment with CP and photoexcited fullerene 
C60 on cancer cells. Fullerene C60 demonstrates unique 
physicochemical properties and biological activity: 
spherical form, nanosize (0.72 nm in dia meter), allocation 
inside hydrophobic regions of cell membranes and ability 
to penetrate into cytoplasm, compatibility with biological 
molecules [12, 13]. Due to extended π-conjugated sys-
tem of molecular orbi tals fullerene C60 absorb UV/Vis 
light efficiently and is able to ge nerate cytotoxic ROS with 
almost 100% quantum yield. Modification of fullerene core 
appears to cause a perturbation of its electronic struc-
ture and hence to reduce the photodynamic potential 
of the molecule [14]. Using pristine fullerene C60 we have 
demonstrated its accumulation inside leukemic cells and 
apoptosis induction after photoexcitation [15].
The aim of this study was to evaluate the viabili-
ty of leukemic cells sensitive (L1210S) and resistant 
(L1210R) to CP, ROS production and free cytosolic 
Ca2+ concentration under CP treatment or combined 
treatment with CP and photoexcited fullerene C60.
MATERIALS AND METHODS
Two leukemic L1210 cell lines — sensitive (L1210S) 
and resistant (L1210R) to CP were used, which were 
kindly provided by Dr. Liudmyla Drobot (V.A. Palladin 
Institute of Biochemistry, the NAS of Ukraine). Cells 
were cultured in RPMI 1640 medium supplemented 
with 10% fetal bovine serum (FBS, Sigma-Aldrich, 
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Germany), 50 μg/ml penicillin and 100 μg/ml strep-
tomycin at 37 °C in a 5% CO2 humidified atmosphere. 
Cells were treated with CP (Sigma, USA) in concentra-
tions 0.1–10 μg/ml.
Stable water colloid solution of fullerene C60 (10–4 M, 
purity >99.5%, nanoparticle average size 50 nm) was 
synthesized in Technical University of Ilmenau (Ger-
many) as described in [16, 17]. Cells in RPMI 1640 me-
dium were incubated for 2 h with or without fullerene 
C60 (10–5 M). Photoactivation of accumulated fullerene 
C60 was done by probes irradiation with light-emitting 
diode lamp (410–780 nm light, irradiance 100 mW 
(2.45 J/сm2), during 2 min).
Cel l  v iabi l i ty  was assessed by the MTT 
[3-(4,5-dimethylthiazol-2-yl)-2.5-diphenyl tetra-
zolium bromide] reduction assay. At indicated time 
points of incubation 200 μl aliquots were removed 
from cell suspensions into the 96-well microplates 
(L1210S/R cells — 1×105/well), 20 μl of MTT solution 
(2.5 μg/ml) was added to each well and the plates 
were incubated for another 2 h. The culture medium 
was then replaced with 100 μl of DMSO, diformazan 
formation was determined by measuring absorption 
at 570 nm with a plate reader (μQuant, BioTek, USA).
ROS production was measured using fluorescent 
probe 2´,7´-dichlorodihydrofluorescein diacetate 
(Sigma, USA), which was added to the cell incu-
bation medium (1×106 cells/ml) in concentration 
5 mM. The fluorescent intensity was measured in real 
time on spectrofluorimeter Shimadzu 150 RF (Japan) 
λ excitation — 480 nm, λ emission — 520 nm [18].
The concentration of free cytosolic Ca2+ was mea-
sured using fluorescent probe Indo-1 (Sigma, USA). 
Cells (3×107/ml) in buffer A consisting of (mM): KCl — 5, 
NaCl — 120, CaCl2 — 1, glucose — 10, MgCl2 — 1, NaH-
CO3 — 4, HEPES — 10, pH 7.4 were loaded with Indo-1AM 
(in concentration 1 mM) in the presence of 0.05% Pluronic 
F-127 (Sigma, USA) for 40 min at 25 °C. Indo-1 fluo-
rescence in cells was recorded using spectrophotom-
eter (Shimadzu RF-510, Japan), λ excitation — 350 nm, 
λ emission — 410 and 495 nm. The concentration of free 
cytosolic Ca2+ was calculated as described in [19].
Data processing and plotting were performed by IBM 
PC using specialized applications Excel 2010 and Origin 
7.0. Statistical analysis was performed using Statis-
tica 6.0 computer program (StatSoft Inc.). Paired Stu-
dent’s t-tests were performed. Differences values p < 
0.05 were considered to be significant.
RESULTS
To estimate the sensitivity of two L1210 cell lines 
to CP, the viability of cells treated with the drug in con-
centration range 0.1–10 μg/ml was studied by MTT 
test. The viability of parental L1210 cells treated with 
CP appeared to be decreased in a dose and duration 
dependent manner (Fig. 1, a). At 24 h of incubation 
the viability of cells treated with 1 μg/ml was decreased 
by 30% while of those treated with 5 μg/ml — by 50%. 
No L1210S cell survival was detected at 72 h after 
treatment with 5 or 10 μg/ml of CP.
Treatment with CP in a range 0.1–10 μg/ml was 
virtually nontoxic to L1210 resistant cells. A slight 
decrease of viability (to approximately 80%) was 
observed at 48 h after the treatment with 5 and 
10 μg/ml CP, but at 72 h the indexes were normalized 
(Fig. 1, b).
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Fig. 1. Cell viability kinetics of L1210S (a) and L1210R (b) cells 
treated with CP in different concentrations (n = 4)
To investigate the effect of combined treatment 
with photoexcited fullerene C60 and CP on suscep-
tibility of L1210 cells to the drug, we used in further 
experiments with long-term cell incubation the CP con-
centration — 1 μg/ml. Cells were preincubated with 
C60 nanoparticles for 2 h, irradiated for photoexcitation 
of accumulated fullerene C60 and incubated for 72 h. 
In the case of combined treatment CP was added just 
before C60 photoexcitation.
Irradiation of cells with or without CP did not change 
the viability of either L1210S or L1210R cells (data 
not shown), while treatment with fullerene C60 was 
followed by slight decrease of both cell lines viability 
(Fig. 2, a, b).
The cytotoxic effect of CP against L1210S appeared 
to be comparable with the effect of photoexcited C60; 
both agents cause the 40% decrease of cell viabili ty 
at 72 h. However, after combined treatment with CP and 
photoexcited C60 the cytotoxic effect was increased and 
CP concentration of 1 μg/ml was proved to be sufficient 
to reach 50% decrease at 48 h as distinct from CP treat-
ment alone (see Fig. 2, a).
We have demonstrated that cytotoxic effect of pho-
toexcited fullerene C60 was realized not only against pa-
rental, but against CP resistant cells as well. Moreover 
while treatment with 1 μg/ml CP alone did not change 
the viability L1210R cells the combined treatment with 
photoexcited C60 and CP allowed to intensify cytotoxic 
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effect and to decrease viability of resistant cells by 68% 
at 48 h of incubation.
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Fig. 2. Cell viability kinetics of L1210S (a) and L1210R (b) cells ex-
posed to fullerene C60 (10–5 M; n = 4), CP (1 μg/ml; n = 4), photoex-
cited C60 (n = 5) and combined treatment with CP and photoexcited 
fullere ne C60 (n = 5)
We supposed that enhancement of cytotoxicity 
after combined treatment with CP and photoexcited 
C60 could be caused by ability to activate early cyto-
plasmic events leading to cell death independently 
of DNA damage. It has been shown, that CP requires 
cytoplasmic generation of ROS and [Са2+]i increase 
to induce apoptosis [20–22].
As we have demonstrated earlier that fullerene 
C60 is accumulated in leukemic Jurkat cell lines, in-
creased ROS production and free cytosolic calcium 
concentration at early period (3 h) after photoex-
citation with further substantial activation of cas-
pase-3 and cell death by mitochondrial-dependent 
pathway at 24 h [15, 23–25]. To confirm this assump-
tion the experiments with CP addition to both cell lines 
at 3 h after photoexcitation of accumulated fullerene 
C60 were carried out.
Sensitive and specific method for ROS produc-
tion evaluation in cells is the use of fluorescent probe 
2´,7´-dichlorodihydrofluorescein diacetate (DCF-DA). 
When DCF-DA was added to untreated cells, the increase 
of fluorescence after 10 min incubation was detected 
corresponding to the endogenous ROS level (Fig. 3). The 
values of free cytosolic calcium concentration in sensi-
tive and resistance cells in control were 125 ± 6 and 
130 ± 4 nM, respectively, and weren’t changed during 
cells incubation (taken for 100%) (Fig. 4).
Treatment of L1210S with CP alone was shown 
to be followed by increasing of both ROS generation 
and [Са2+]i at early period after CP addition while after 
treatment of L1210S with the drug neither ROS nor [Са2+]
i levels were changed (see Fig. 3, a, 4, a). In contrast 
to CP photoexcited fullerene C60 induced ROS production 
and [Са2+]i elevation not only in L1210S, but in L1210R cells 
as well (see Fig. 3, 4).
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Fig. 3. The kinetics of ROS production in L1210S (a) and 
L1210R (b) cells after exposition to CP (n = 3), photoexcited fulle-
rene C60 (n = 4) and combined treatment with CP and photoexcited 
fullerene C60 (n = 4)
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Fig. 4. Ca2+ concentration in L1210S (a) and L1210R (b) cells 
exposed to CP — 1 (n = 3), photoexcited fullerene C60 — 2 (n = 4) 
and combined treatment with CP and photoexcited fullerene 
C60 — 3 (n = 4)
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But the most strongly pronounced increase 
of DCF and indo-1 fluorescent signals in both L1210S 
and L1210R cells were detected in dynamics after 
combined treatment with CP and photoexcited 
fullerene C60 indicating on substantial disturbance 
of intracellular redox status and calcium homeostasis 
(see Fig. 3, 4).
The obtained data demonstrate the synergic 
cytotoxic effect of CP and photoexcited fullerene 
C60 against L1210R leukemic cells. The combined 
treatment with these agents is followed by intensifi-
cation of ROS dependent pathways of cell death and 
allows not only to decrease effective concentration 
of CP against parental L1210 cells, but to restore sen-
sibility of resistant cells to the drug.
DISCUSSION
Recent studies [3, 6, 21, 22] demonstrate that ac-
tivation of the signaling pathways to apoptosis which 
occurs in cytoplasm independently of nuclear is the al-
ternative to DNA damaging mechanism of CP toxi city 
against cancer cell. Searching for the ways to en-
hance CP extranuclear cytotoxic effects with the use 
of nanotechnology opens the possibility to increase 
the therapeutic efficiency of the drug.
We studied the ef fect of  CP at  a range 
1–10 μg/ml against parental and drug-resistant leuke-
mic L1210 cells. Early intensiﬁ cation of ROS production 
and Ca2+ increase after treatment with 1 μg/ml was de-
tected in L1210S cells. No decrease of L1210R cells vi-
ability and no changes in ROS or [Ca2+]i levels at the early 
period of treatment with 1 μg/ml CP were detected.
These data are in agreement with the studies which 
reported that CP-induced extranuclear effects involve 
intensification of ROS generation due to CP upregula-
tion of nicotinamide adenine dinucleotide phosphate 
oxidases (NOX-1 and NOX-4) and ER stress induc-
tion [20, 26]. It is also shown that CP could provoke 
elevation of cytosolic calcium concentration by an in-
creased Ca2+ uptake from the extracellular space (me-
diated through plasma membrane calcium channel) 
or by Ca2+ release through IP3 receptors of endoplas-
mic reticulum [21, 27].
To overcome drug resistance in L1210R cells 
the combined treatment with photoexcited fullerene 
C60 and CP was used. The results indicated that 
combined treatment improved the cytotoxic effect 
of CP in L1210R cells by increase of ROS production 
and free cytosolic calcium concentration and decrease 
of cells viability. We suggested that this alteration 
in L1210R cells sensitivity to CP could be explained 
by the ability of fullerene C60 to affect and modify some 
mechanisms of cell drug resistance development: 
platinum compounds transport through the plasma 
membrane, antioxidative system activity (detoxifica-
tion by glutathione conjugates), induction of apoptotic 
pathways, calcium homeostasis maintenance [3, 28–
33]. Thus, fullerene derivatives are able to reactivate 
endocytosis in cancer cells and to promote CP ac-
cumulation [8]. Fullerene C60 is shown to be located 
in the plasma membrane and intermembrane space 
of mitochondria with further intensification of ROS 
in mitochondrial electron transport chain [24, 34]. 
It is also shown that cancer cells have genetically re-
modulated system of calcium homeostasis: underfilled 
ER calcium pool and reduced of SOCE (store-operated 
calcium entry through plasma membrane) directed 
to prevent Ca2+-dependent way of apoptosis. We have 
earlier shown that photoexcited C60 induced the in-
crease of SOCE, depletion of mitochondrial Ca2+-pool, 
cytochrome c release from mitochondria and activate 
Ca2+-dependent apoptotic pathway [23].
Consequently, we supposed that sensitivity en-
hancement of L1210R cells to CP induced by combined 
treatment was connected with properties of photoexcit-
ed fullerene C60 to affect on auxiliary intracellular targets 
beside that which were involved in CP cytotoxic effect.
This suggests that combined treatment with CP and 
photoexcited fullerene C60 is followed by synergistic 
anticancer effect of both compounds and allows to in-
crease cytotoxicity against leukemic L1210 cells and 
to restore sensibility of L1210 resistant cells to CP by en-
hancing extranuclear proapoptotic effects of the drug.
The proposed model of combined treatment can 
be helpful in developing the approaches to decrease 
anticancer drug’s toxic dose and to optimize the me-
thods of photodynamic therapy.
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